Skip to main content


From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications. 

Intellectual Property

The following are protected by patents in the United States and in foreign jurisdictions for Moderna Inc.

Spikevax™ (mRNA-1273 COVID-19 VACCINE)

US 10,898,574

US 10,703,789

US 10,702,600

US 10,577,403

US 10,442,756

US 10,266,485

US 10,064,959

US 9,868,692